- Home
- Publications
- Publication Search
- Publication Details
Title
Histone deacetylase 1 and 2 in mesenchymal tumors
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 25, Issue 2, Pages 222-230
Publisher
Springer Nature
Online
2011-10-28
DOI
10.1038/modpathol.2011.157
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas
- (2015) Wilko Weichert et al. NEOPLASIA
- The significance of strong histone deacetylase 1 expression in the progression of prostate cancer
- (2011) YooHyun Song et al. HISTOPATHOLOGY
- The molecular signature of oncofusion proteins in acute myeloid leukemia
- (2010) Joost H.A. Martens et al. FEBS LETTERS
- SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
- (2010) V. Novotny-Diermayr et al. MOLECULAR CANCER THERAPEUTICS
- EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor
- (2010) L Su et al. ONCOGENE
- Histone deacetylase inhibitors as anti-neoplastic agents
- (2009) Nicolas Batty et al. CANCER LETTERS
- Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays
- (2009) Hongwei Cheng et al. HUMAN PATHOLOGY
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation
- (2009) G. H. S. Richter et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Histone Deacetylase Inhibitors Reverse SS18-SSX-Mediated Polycomb Silencing of the Tumor Suppressor Early Growth Response 1 in Synovial Sarcoma
- (2008) J. M. Lubieniecka et al. CANCER RESEARCH
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo
- (2008) W. Weichert et al. CLINICAL CANCER RESEARCH
- SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway
- (2008) A Hrzenjak et al. JOURNAL OF PATHOLOGY
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
- (2008) Shuzhen Liu et al. MOLECULAR CANCER THERAPEUTICS
- EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma
- (2008) Leah A. Owen et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More